CGC · Canopy Growth Corporation

Current Thesis

Canopy Growth's medical-cannabis recovery remains a policy-sensitive rebound thesis, confirmed by a weekly close above $1.00 and invalidated by a daily close below $0.84. These are research conditions anchored to the market's 2026-08-28 close and the historical downside reference identified on 2026-07-24, respectively.

The operating evidence remains the 2026-08-07 report: first-quarter fiscal 2027 revenue of C$81.2 million, up 13% year over year, and an adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) loss of C$3.2 million. Since the 2026-09-06 assessment, Canopy announced broader Australian medical-cannabis formats on 2026-09-08 and issued a proxy reminder on 2026-09-14. Those announcements extend the medical-business and corporate-action stories; they do not establish a new earnings result. Canopy news releases

The narrative is maturing — an inference from the completed 2026-07-15 rescheduling hearing, the 2026-08-17 closing briefs cited in the September assessment, and the approaching shareholder meeting. The 2026-09-18 adjusted close of $0.93 remains below the 2026-08-28 close of $1.00. Those observations establish price weakness; the sample is too small to support a claim about investor flows.

Bullish and bearish views on Canopy Growth Corporation

The model's bull view on Canopy Growth Corporation (CGC), in brief: Medical revenue supplies operating evidence. The bear view: Cash consumption exceeds adjusted losses. Both cases follow in full.

Bull Case

• Medical revenue supplies operating evidence. Canopy's 2026-08-07 results reported Canadian medical revenue of C$25.8 million, up 22% year over year, and international cannabis revenue of C$9.6 million, up 10%. The rebound case loses operating support if subsequent reported revenue in either business falls below those quarterly amounts.
• Losses narrowed alongside margin improvement. The 2026-08-07 report showed a C$3.2 million adjusted EBITDA loss and a 31% adjusted gross margin, compared with 25% a year earlier. A subsequent quarterly adjusted EBITDA loss greater than C$3.2 million would contradict continued loss improvement.
• Australia adds a dated development. Canopy announced expanded Australian medical-cannabis formats and formulations on 2026-09-08. Incremental revenue attributable to that announcement is missing, so the launch supports product activity without establishing financial acceleration. Company announcement listing

Bear Case

• Cash consumption exceeds adjusted losses. Canopy reported C$25.7 million of free cash outflow for the quarter ended 2026-06-30, alongside the C$3.2 million adjusted EBITDA loss announced on 2026-08-07. Another quarterly free cash outflow at or above C$25.7 million would undermine the argument that earnings improvement is reaching cash generation.
• The next vote concerns capital structure. The definitive proxy proposes a consolidation ranging from one new share for every five to fifteen existing shares, with implementation discretionary. Approval on 2026-09-25 would establish authorization, not an operating improvement. 2026 definitive proxy
• The rebound remains unconfirmed. The supplied adjusted series shows a $0.93 close on 2026-09-18 and a three-month price decline of 2.4%. A weekly close above the historical $1.00 reference would contradict the present assessment of an unconfirmed recovery.

Setup & Price Structure

The measured 2026-09-18 reference close is $0.93. The same adjusted series reports a 14-day relative strength index (RSI) of 27.3. That indicator describes recent price momentum; it does not establish that a rebound has begun.

The $1.00 close recorded on 2026-08-28 supplies the recovery test. The $0.84 downside reference identified on 2026-07-24 remains the thesis-break threshold; it is a historical reference, not a newly verified current low. No moving-average series, current short-interest figure or dated insider-transaction record is available in this assessment.

The observable event concentration is the 2026-09-25 shareholder meeting, confirmed by Canopy's calendar. Neither that proximity nor the low RSI establishes crowded positioning. Evidence strength remains low because the latest measured price has not cleared the recovery condition. Company meeting calendar

Catalyst Calendar (next 30 days)

• 2026-09-23 — Proxy submission deadline. The filed voting materials specify 1:00 p.m. Eastern time. This is a procedural milestone ahead of the consolidation vote, not a policy decision. Filed voting materials
• 2026-09-25 — Annual shareholder meeting. Canopy schedules the webcast for 1:00 p.m. Eastern time; the consolidation proposal makes this the next confirmed company catalyst. The result establishes whether the board receives the requested authority. Company event notice, definitive proxy

As of 2026-09-20, the reviewed Drug Enforcement Administration (DEA) materials do not establish a dated recommendation or final decision within this calendar window. The rescheduling outcome therefore remains an undated dependency rather than a scheduled catalyst. DEA proceeding materials

What Would Change Our Mind

Loss of the historical downside reference would end the rebound thesis: a daily close below $0.84 is the published failure condition. Conversely, a weekly close above the market's 2026-08-28 reference of $1.00 would satisfy the price-recovery case before that failure condition occurs.

Operating confirmation requires a subsequent quarterly adjusted EBITDA loss smaller than the C$3.2 million reported on 2026-08-07, accompanied by free cash outflow below the C$25.7 million reported for the quarter ended 2026-06-30. A consolidation authorization at the 2026-09-25 meeting would not satisfy either financial test.

Correlation Notes

This assessment treats Canopy as a single-name setup. The 2026-08-07 results provide company-specific medical and international revenue evidence, while the DEA proceeding supplies a potential shared cannabis-sector catalyst. Shared exposure is an inference, not a measured return correlation.

No synchronized peer-return series is available for the 2026-09-20 assessment, so neither sector leadership nor a correlation coefficient can be established. The $0.93 adjusted close on 2026-09-18 measures Canopy's own structure; it cannot establish broader cannabis participation.